



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)

A61P 27/02 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2023/060329

(22) International Filing Date:

09 January 2023 (09.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/297,787 09 January 2022 (09.01.2022) US

63/374,878 07 September 2022 (07.09.2022) US

(71) Applicant: KRIYA THERAPEUTICS, INC. [US/US];

380 Portage Avenue, Palo Alto, California 94306 (US).

(72) Inventors: STONE, Michele; c/o Kriya Therapeutics, Inc.,

1100 Island Drive, Suite 203, Redwood City, California

94065 (US). HEAH, Theresa; c/o Kriya Therapeutics, Inc.,

1100 Island Drive, Suite 203, Redwood City, California

94065 (US). GUPTA, Nachi; c/o Kriya Therapeutics, Inc.,

1100 Island Drive, Suite 203, Redwood City, California

94065 (US). SHEN, Weiran; c/o Kriya Therapeutics, Inc.,

1100 Island Drive, Suite 203, Redwood City, California

94065 (US). CEPEDA, Diana; c/o Kriya Therapeutics,

Inc., 1100 Island Drive, Suite 203, Redwood City, Califor-

nia 94065 (US). CASTELLANOS, Ruth; c/o Kriya Ther-

apeutics, Inc., 1100 Island Drive, Suite 203, Redwood City,

California 94065 (US).

(74) Agent: NANNENGA-COMBS, Bonnie W. et al.;

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C, 1100

New York Avenue, NW, Washington, District of Columbia

20005 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,

KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,

LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,

NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,

RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,

GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: VECTOR CONSTRUCTS FOR DELIVERY OF NUCLEIC ACIDS ENCODING THERAPEUTIC ANTI-IGF-1R ANTIBODIES AND METHODS OF USING THE SAME

(57) Abstract: The present disclosure provides gene therapy vectors, antibody expression cassettes, and vectors comprising a nucleic acid encoding a therapeutic anti-IGF-1R antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof, delivery vectors (e.g., viral vectors) comprising gene therapy constructs a nucleic acid encoding a therapeutic anti-IGF-1R antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof, compositions comprising the same, and methods of using the same. Some aspects of the disclosure are directed to a recombinant adeno-viral vector (rAAV) particle for delivery of a nucleic acid encoding a therapeutic anti-IGF-1R antibody (e.g., a monoclonal antibody) or an antigen binding fragment thereof.

